Martin Tolar
Company: Alzheon
Job title: Founder, President & CEO
Seminars:
Live Q&A With Your Expert Speakers 4:20 pm
day: Day One
ALZ-801 Phase 3 Program: A Targeted Oral Disease Modifying Therapy for Alzheimer’s Disease 3:10 pm
day: Day One
Kick-off Panel Discussion 9:10 am
Overview of recent encouraging clinical case studies across the industry – what are the treatments that are around the corner promising results? What has Biogen’s aducanumab story taught us? What new research has been revealed to shine light on the mechanisms that are driving neurodegenerative pathology? Is there space for all of these different modalities…Read more
day: Day One